TuHURA Biosciences Appoints Dr. Craig L. Tendler to Boost Oncology Development Efforts

TuHURA Biosciences Strengthens Leadership with Key Appointment in Oncology Development

TuHURA Biosciences, Inc. is making significant strides in its pursuit of innovative cancer therapies as it announces the strategic appointment of Dr. Craig L. Tendler, who will extend his role with the company. Dr. Tendler, a seasoned expert in drug development and medical affairs with over 29 years of experience, assumes responsibilities akin to those of a Chief Medical Officer while also serving on TuHURA's Board of Directors. His extensive background includes securing more than 30 oncology regulatory approvals and overseeing 15 new medical entity approvals, which highlights his ability to navigate the complex landscape of cancer therapeutics.

Dr. Tendler's expertise in hematologic malignancies positions him well to guide the development of TuHURA’s promising VISTA inhibiting antibody, TBS-2025. This therapy aims to tackle pressing challenges such as VISTA’s immunosuppressive role in acute myeloid leukemia (AML) and other blood-related cancers. Dr. James Bianco, President and CEO of TuHURA, expresses high confidence in Dr. Tendler's potential to influence the development trajectory of TBS-2025 and improve outcomes for patients, especially those with NPM1 mutated AML. The collaborative effect of leveraging Dr. Tendler's insights from prior work on menin inhibitor bleximenib could significantly enhance the clinical prospects of TBS-2025.

The recent feedback from the FDA's Division of Hematologic Malignancies I on the early development plan of TBS-2025 adds an encouraging dimension to TuHURA's research efforts. The company aims to accelerate the clinical progression of TBS-2025, exploring its potential both as a monotherapy and in combination with menin inhibitors, a category of therapies where Dr. Tendler has substantial experience. His appointment is not merely a reinforcement of leadership but reflects TuHURA's unwavering commitment to advancing therapies that address significant unmet medical needs in the field of oncology.

In other news, TuHURA continues to focus on enhancing patient outcomes through its innovative pipeline. The company's strategic moves, including hiring experienced personnel like Dr. Tendler, are pivotal as it endeavors to break new ground in immuno-oncology. This commitment to attracting top-tier talent underscores TuHURA’s mission to bring effective therapies to patients grappling with difficult-to-treat cancers.